Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384834 | 0.89 | HDAC4 (0.46) | SLC6A3SLC6A4CHRM2CHRM1OPRM1 | |
| SCHEMBL7047849 | 0.80 | SLC6A3 (0.47) | SLC6A3SLC6A4CHRM2CHRM1CCR2 | |
| SCHEMBL16506943 | 0.80 | SLC6A3 (0.55) | SLC6A3SLC6A4CHRM2CHRM1OPRM1 | |
| SCHEMBL2795429 | 0.79 | AKR1C3 (0.58) | SLC6A3SLC6A4CHRM2CHRM1CCR2 | |
| SCHEMBL2023 | 0.77 | OPRM1 (0.48) | SLC6A3SLC6A4CHRM2CHRM1CCR2 | |
| SCHEMBL7366120 | 0.77 | CHRM2 (0.49) | SLC6A3SLC6A4CHRM2CHRM1OPRM1 | |
| SCHEMBL3516988 | 0.76 | AKR1C3 (0.58) | SLC6A3SLC6A4CHRM2CHRM1CCR2 | |
| SCHEMBL16507270 | 0.76 | CHRM2 (0.43) | SLC6A3SLC6A4CHRM2CHRM1OPRM1 | |
| SCHEMBL3517260 | 0.75 | CHRM2 (0.54) | SLC6A3SLC6A4CHRM2CHRM1OPRM1 | |
| SCHEMBL4835678 | 0.75 | ATM (0.45) | SLC6A4CHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970090-B1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | KNOLL GMBH (DE) | 2002-06-05 | — | — | EP | disclosed |
| US-6187802-B1 | 3-(1-(3,4-DICHLOROPHENYL)CYCLOBUTYL)-5,6-DIHYDROIMIDAZO(2,1-B) THIAZOLE, FOR EXAMPLE; ADMINISTERING TO TREAT DEPRESSION, ANXIETY, PARKINSON'S DISEASE, OBESITY, COGNITIVE DISORDERS, SEIZURES, AND FOR NEUROPROTECTION AGAINST STROKE | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-02-13 | — | — | US | disclosed |
| EP-0970090-A1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Knoll AG (DE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998041528-A1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |